CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS, AL and CML
Status:
Suspended
Trial end date:
2026-02-01
Target enrollment:
Participant gender:
Summary
This study will evaluate combining stem cells from the patient's matched sibling donor (a
standard CD34-selected transplant) with a second infusion of white blood cells called "CD8
memory T-cells" from their sibling donor.
Phase:
Phase 2
Details
Lead Sponsor:
Stanford University
Collaborators:
National Cancer Institute (NCI) National Institutes of Health (NIH)